Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis

BACKGROUND: Dabigatran is one of the three newer oral anticoagulants (OACs) recently approved in the United States for stroke prevention in non-valvular atrial fibrillation (NVAF) patients. The objective of this study was to identify patient, healthcare provider, and health plan factors associated w...

Descripción completa

Detalles Bibliográficos
Autores principales: AbuDagga, Azza, Stephenson, Judith J, Fu, An-Chen, Kwong, Winghan Jacqueline, Tan, Hiangkiat, Weintraub, William S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112613/
https://www.ncbi.nlm.nih.gov/pubmed/25034699
http://dx.doi.org/10.1186/1472-6963-14-310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112613/
https://www.ncbi.nlm.nih.gov/pubmed/25034699
http://dx.doi.org/10.1186/1472-6963-14-310

Ejemplares similares